Literature DB >> 15971335

RBE of carbon ions: experimental data and the strategy of RBE calculation for treatment planning.

W K Weyrather1, G Kraft.   

Abstract

The main reason for the application of heavy ions like carbon in radiotherapy is the enhanced relative biological effectiveness RBE. In contrast to neutrons where RBE is widely independent from penetration depth, high energy carbon beams have a low RBE at the entrance and a high RBE in the target-volume. Therefore, the side effects to normal tissue are small, while the tumor response can be maximized. In the paper, experimental RBE values for inactivation are compiled, that demonstrate the RBE dependence from the repair capacity. In a theoretical approach, the local effect model (LEM), this dependence is used to calculate clinical RBE. Examples for clinical RBEs are given that have been applied to patient treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15971335     DOI: 10.1016/s0167-8140(04)80041-0

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

1.  The potential impact of relative biological effectiveness uncertainty on charged particle treatment prescriptions.

Authors:  B Jones; T S A Underwood; R G Dale
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  DNA damage intensity in fibroblasts in a 3-dimensional collagen matrix correlates with the Bragg curve energy distribution of a high LET particle.

Authors:  Andres I Roig; Suzie K Hight; John D Minna; Jerry W Shay; Adam Rusek; Michael D Story
Journal:  Int J Radiat Biol       Date:  2010-03       Impact factor: 2.694

Review 3.  Heavy charged particle radiobiology: using enhanced biological effectiveness and improved beam focusing to advance cancer therapy.

Authors:  Christopher Allen; Thomas B Borak; Hirohiko Tsujii; Jac A Nickoloff
Journal:  Mutat Res       Date:  2011-03-03       Impact factor: 2.433

4.  Ways to unravel the clinical potential of carbon ions for head and neck cancer reirradiation: dosimetric comparison and local failure pattern analysis as part of the prospective randomized CARE trial.

Authors:  Thomas Held; Thomas Tessonnier; Henrik Franke; Sebastian Regnery; Lukas Bauer; Katharina Weusthof; Semi Harrabi; Klaus Herfarth; Andrea Mairani; Jürgen Debus; Sebastian Adeberg
Journal:  Radiat Oncol       Date:  2022-07-08       Impact factor: 4.309

Review 5.  Particle therapy in the future of precision therapy.

Authors:  Lukas Schaub; Semi Ben Harrabi; Juergen Debus
Journal:  Br J Radiol       Date:  2020-08-14       Impact factor: 3.629

6.  Full Monte Carlo-Based Biologic Treatment Plan Optimization System for Intensity Modulated Carbon Ion Therapy on Graphics Processing Unit.

Authors:  Nan Qin; Chenyang Shen; Min-Yu Tsai; Marco Pinto; Zhen Tian; Georgios Dedes; Arnold Pompos; Steve B Jiang; Katia Parodi; Xun Jia
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-09-12       Impact factor: 7.038

7.  The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.

Authors:  Hirokazu Hirakawa; Hiroshi Fujisawa; Aya Masaoka; Miho Noguchi; Ryoichi Hirayama; Momoko Takahashi; Akira Fujimori; Ryuichi Okayasu
Journal:  Cancer Med       Date:  2015-01-13       Impact factor: 4.452

8.  Influence of acute hypoxia and radiation quality on cell survival.

Authors:  Walter Tinganelli; Ning-Yi Ma; Cläre Von Neubeck; Andreas Maier; Corinna Schicker; Wilma Kraft-Weyrather; Marco Durante
Journal:  J Radiat Res       Date:  2013-07       Impact factor: 2.724

9.  Differences in Phosphorylated Histone H2AX Foci Formation and Removal of Cells Exposed to Low and High Linear Energy Transfer Radiation.

Authors:  Thomas Ernst Schmid; Olga Zlobinskaya; Gabriele Multhoff
Journal:  Curr Genomics       Date:  2012-09       Impact factor: 2.236

10.  The Relative Biological Effect of Spread-Out Bragg Peak Protons in Sensitive and Resistant Tumor Cells.

Authors:  Yu-Fen Lin; Benjamin P Chen; Wende Li; Zoltan Perko; Yi Wang; Mauro Testa; Robert Schneider; Hsaio-Ming Lu; Leo E Gerweck
Journal:  Int J Part Ther       Date:  2018-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.